Sugi Predict

Sugi Predict / Compounds / SCHEMBL4384529

SCHEMBL4384529

SCHEMBL4384529

CC(O)c1cccc(N)n1

nearest known ligand 0.46

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ NOS3 P29474 2/20 0.46
▸ NOS2 P35228 2/20 0.46
▸ XIAP P98170 1/20 0.43
▸ BIRC2 Q13490 1/20 0.43
▸ IDH1 O75874 3/20 0.38
▸ ASIC3 Q9UHC3 1/20 0.38
▸ MCHR1 Q99705 4/20 0.37
▸ NOS1 P29475 1/20 0.36
▸ IRAK4 Q9NWZ3 2/20 0.35
▸ PLAU P00749 1/20 0.35
▸ NCF1 P14598 1/20 0.35
▸ HSD11B1 P28845 3/20 0.35
▸ TDP1 Q9NUW8 1/20 0.34
▸ GRM4 Q14833 1/20 0.33
▸ KCNA5 P22460 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30670465 1.00 NOS3 (0.46) NOS3NOS2XIAPBIRC2IDH1
SCHEMBL29860803 0.84 PGK1 (0.41) IRAK4HSD11B1TDP1
SCHEMBL4273303 0.84 PGK1 (0.41) IRAK4HSD11B1TDP1
SCHEMBL179264 0.82 NOS2 (0.50) NOS3NOS2XIAPBIRC2IDH1
SCHEMBL24736329 0.80 NOS3 (0.48) NOS3NOS2XIAPBIRC2IDH1
SCHEMBL30278247 0.80 NOS3 (0.48) NOS3NOS2XIAPBIRC2IDH1
SCHEMBL4326351 0.80 NOS3 (0.48) NOS3NOS2XIAPBIRC2IDH1
SCHEMBL22521536 0.78 NOS2 (0.46) NOS3NOS2XIAPBIRC2IDH1
SCHEMBL17559548 0.78 NOS3 (0.42) NOS3NOS2XIAPBIRC2IDH1
SCHEMBL31085146 0.77 UGT2B7 (0.39) IRAK4HSD11B1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240208981-A1 NITROGEN-CONTAINING HETEROCYCLIC POLYCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) 2024-06-27 — — US disclosed
US-20240208981-A1 NITROGEN-CONTAINING HETEROCYCLIC POLYCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) 2024-06-27 — — US disclosed
EP-4310089-A1 NITROGEN-CONTAINING HETEROCYCLIC POLYCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF Shanghai Hansoh Biomedical Co., Ltd. (CN) 2024-01-24 — — EP disclosed
EP-4310089-A1 NITROGEN-CONTAINING HETEROCYCLIC POLYCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF Shanghai Hansoh Biomedical Co., Ltd. (CN) 2024-01-24 — — EP disclosed
CN-116981670-A Polycyclic compound containing nitrogen heterocycle, preparation method and application thereof 上海翰森生物医药科技有限公司 2023-10-31 — — CN disclosed
WO-2022194122-A1 NITROGEN-CONTAINING HETEROCYCLIC POLYCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF 上海翰森生物医药科技有限公司 2022-09-22 — — WO disclosed
EP-1893609-B1 N-(PYRIDIN-2-YL)-SULFONAMIDE DERIVATIVES PFIZER (US) 2009-11-18 — — EP disclosed
EP-1893609-B1 N-(PYRIDIN-2-YL)-SULFONAMIDE DERIVATIVES PFIZER (US) 2009-11-18 — — EP disclosed
EP-1622912-B1 2-ALKYNYL-AND 2-ALKENYL-PYRAZOLO- [4,3-E ] -1,2,4-TRIAZOLO- [1,5-C] -PYRIMIDINE ADENOSINE A2A RECEPTOR ANTAGONISTS SCHERING CORP (US) 2009-05-27 — — EP disclosed
US-7462634-B2 N-(pyridin-2-yl)-sulfonamide derivatives AGOURON PHARMACEUTICALS, INC. (US) 2008-12-09 — — US disclosed
US-20070072914-A1 N-(pyridin-2-yl)-sulfonamide derivatives AGOURON PHARMACEUTICALS, INC. 2007-03-29 — — US disclosed
US-20070072914-A1 N-(pyridin-2-yl)-sulfonamide derivatives AGOURON PHARMACEUTICALS, INC. 2007-03-29 — — US disclosed
WO-2006134467-A1 N-(PYRIDIN-2-YL)-SULFONAMIDE DERIVATIVES PFIZER INC. (US) 2006-12-21 — — WO disclosed
WO-2005103055-A1 PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PYRIMIDINE ADENOSINE A2A RECEPTOR ANTAGONISTS SCHERING CORPORATION (US) 2005-11-03 — — WO disclosed
US-6576643-B2 Compounds containing dibenzo(A,D)cycloheptene or dibenz(B,F)oxepine derivatives are useful for treating osteoporosis, cardiovascular diosrders, cancer and inflammation SMITHKLINE BEECHAM CORPORATION 2003-06-10 — — US disclosed
US-20020091264-A1 Vitronectin receptor antagonists SMITHKLINE BEECHAM CORPORATION 2002-07-11 — — US disclosed
CN-1278250-A Vitronectin receptor antagonists SMITHKLINE BEECHAM CORP (US) 2000-12-27 — — CN disclosed
EP-1025090-A4 VITRONECTIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2000-11-08 — — EP disclosed
EP-1025090-A1 VITRONECTIN RECEPTOR ANTAGONISTS SmithKline Beecham Corporation (US) 2000-08-09 — — EP disclosed
WO-1999015508-A1 VITRONECTIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1999-04-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020091264-A1 Vitronectin receptor antagonists CALCR, ADGRF1, CALCRL NOS3 2265/4885NOS2 2467/4885XIAP 3855/4885
US-20240208981-A1 NITROGEN-CONTAINING HETEROCYCLIC POLYCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF HCRTR1, HCRTR2, CCKBR NOS3 383/4885NOS2 262/4885XIAP 2706/4885
US-20070072914-A1 N-(pyridin-2-yl)-sulfonamide derivatives HSD11B1, HSD3B1, HSD11B2 NOS3 1952/4885NOS2 2065/4885XIAP 4489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.